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Abstract
The aim of this study was to investigate immune response and its prognostic significance in colon carcinomas
using the previously described Immunoscore (IS). A population-based series of 779 colorectal cancers, oper-
ated on between 2000 and 2010, were classified according to tumour, node, metastasis (TNM) status, mis-
match repair (MMR), and BRAF mutation status. Rectal cancer cases (n5 203) were excluded as a high
proportion of these patients received preoperative neoadjuvant chemoradiotherapy. Tissue microarray (TMA)
samples collected from the tumour centre and invasive front were immunostained for CD3 and CD8. Lympho-
cytes were then digitally calculated to categorize IS from grade 0 to 4. Samples adequate for IS were available
from 510 tumours. IS was significantly associated with AJCC/UICC stage, T stage, lymph node and distant
metastases, perineural and lymphovascular invasion, MMR status, and BRAF mutation status. For IS0, IS1, IS2,
IS3 and IS4, respectively, the 5-year disease-free survival (DFS) rates were 59, 68, 78, 83 and 94%
(p< 0.001); 5-year disease-specific survival (DSS) rates were 47, 55, 75, 80, and 89% (p< 0.001); and
5-year overall survival (OS) rates were 40, 44, 66, 61, and 76% (p<0.001). IS was also prognostic for DFS,
DSS, and OS within subsets of microsatellite-stable (MSS) and microsatellite-instable (MSI) disease. Multivari-
able analysis showed that IS, AJCC/UICC stage, lymphovascular invasion, and lymph node ratio in AJCC/UICC
stage III disease were independent prognostic factors for DFS, DSS, and OS. Age was an independent prognos-
tic factor for DSS and OS. Gender and BRAF mutation were independent prognostic factors for OS. In conclu-
sion, IS differentiated patients with poor versus improved prognosis in MSS and MSI disease and across AJCC/
UICC stages. IS, AJCC/UICC stage, lymphovascular invasion, and lymph node ratio in AJCC/UICC stage III dis-
ease were independent prognostic factors for DFS, DSS, and OS.
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Introduction
Colorectal cancer (CRC) is the fourth most common
malignancy worldwide, occurring with an estimated
annual incidence of approximately 1.3 million cases
and causing over 600 000 deaths per year [1]. The
American Joint Committee on Cancer/Union for
International Cancer Control (AJCC/UICC) has pub-
lished the most reliable histopathological method for
CRC staging, which shows great prognostic
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significance even though prognosis can vary substan-
tially even among patients within the same stage [2].
It is estimated that 30 to 50% of colon cancers recur
during follow-up despite optimal primary treatment
[3]. Biological differences reportedly influence
tumour behaviour and prognosis [4].
Recent findings indicate that CD31, CD81, and
CD45RO1 lymphocytes play important roles in tumour
growth suppression, both in the tumour centre and at the
invasive front of primary and metastatic CRCs [5–8].
Therefore, investigations of immune responses may pro-
vide more detailed information regarding CRC prognosis.
The Immunoscore (IS) has been developed to
describe immune responses in CRC. The IS classifi-
cation is based on CD31 and CD81 lymphocyte cell
counts in representative areas of the tumour centre
and invasive front. The Immunoscore is reportedly a
significant prognostic factor for colon and rectal can-
cer [7–9]. It has been suggested that use of the IS in
combination with AJCC/UICC staging could lead to
better determination of tumour prognosis [10].
CRCs can also be classified according to their mis-
match repair (MMR) capacity into MMR-deficient and
MMR-proficient tumours, also termed microsatellite-
instable (MSI) or microsatellite-stable (MSS) cancers.
The MMR deficiency pathway induces hypermutated
MSI cancers that differ from MSS cancers in their muta-
tion profile and biological behaviour [11]. MSI colorectal
cancers show improved prognosis compared to MSS can-
cers [12–14]. Due to their abundant mutations, MSI
tumours exhibit aberrant neoantigens that can induce
immune responses against cancer cells [15]. BRAF muta-
tion plays a specific role in several tumour types and has
been associated with worse prognosis in MSS colon car-
cinoma [16–18]. Other factors also reportedly have prog-
nostic significance in CRC, such as perineural and
lymphovascular invasion [19,20], as well as lymph node
ratio (LNR) in stage III disease [21].
The aim of our study was to define the prognostic
significance of IS in a large population-based cohort
of colon cancer patients classified into four AJCC/
UICC stages using current histopathological criteria.
We particularly wanted to assess the association of
IS with other known prognostic factors, such as
MMR/BRAF mutation status, perineural or lympho-
vascular invasion, and lymph node ratio.
Material and methods
Patients
This study was performed at the Central Hospital of
Central Finland, which serves a defined catchment area
of about 274 000 people. Tissue microarray (TMA) data
were available for representative tumour samples from
799 patients who underwent operations at our hospital
from 2000 to 2010. For 779 of these cases, good quality
immunohistochemical (IHC) staining of a representative
tumour sample for MSI was also available. Patients with
rectal cancer (n5 203) were excluded as a high propor-
tion of these patients underwent preoperative neoadju-
vant chemoradiotherapy, which may influence immune
response. Tissue cores adequate for IS determination
were available from 510 colon cancers.
We reviewed hospital records to extract information
regarding treatment and tumour recurrence. Causes of
death were reviewed and updated in December 2015
from the Finnish Cause of Death Registry. Macroscopic
and histological examination of tumour tissue was per-
formed by an experienced histopathologist following
AJCC guidelines (5th and 6th edition). The lymph
node ratio (LNR) was calculated as the proportion of
metastatic lymph nodes from the total number of lymph
nodes examined. AJCC/UICC stage III patients were
divided into three similar-sized groups based on LNR:
<0.12, 0.12 to 0.30, and >0.30. A 6-month course of
adjuvant postoperative chemotherapy with either 5-
fluorouracil (FU) and oral folinic acid, oral capecitabine
with or without oxaliplatin, or the FOLFOX regimen
was prescribed to medically fit patients having stage III
tumours or high-risk stage II disease (T4 or T3 with
perineural or lymphovascular invasion).
Tumour sampling
TMA blocks were prepared from formalin-fixed paraffin-
embedded tissue (FFPE) samples. Tissue cores (diameter,
0.6 mm) were punched out and were set into a recipient
paraffin block using the Manual Tissue Microarrayer
MTA-1 (Beecher Instruments, Inc.). We obtained one
core from normal tissue, two cores from the tumour
centre, and two cores from the tumour invasive front. The
TMA blocks were cut into 2-lm-thick sections.
Immunohistochemistry
For all included tumours, we performed a universal
IHC screening for loss of MMR protein expression and
BRAF mutation, as previously described [12]. For 21
cases, the BRAF staining was unsuccessful or left indif-
ferent. The following monoclonal antibodies for were
used immunohistochemical staining: MLH1 (Novocas-
tra NCL-L-MLH1, clone ES05), MSH2 (Oncogene
Research Products NA27, clone FE11), MSH6 (Cell
Marque 287M-16, clone 44), PMS2 (BD Pharmingen
556415, clone A16–4), BRAF V600E monoclonal anti-
body (Spring Bioscience E19292, clone VE1).
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TMA block sections were immunohistochemically
stained using CD3 (Novocastra, NCL-L-CD3, clone
PS1) and CD8 (Thermo Scientific, RM-9116, clone
SP16) antibodies, both diluted 1:100, following
standard procedures using the BOND-III staining
instrument (Leica Biosystems) and Bond Polymer
Refine Detection Kit (Leica Biosystems). Samples
were incubated with antibody dilutions for 30 min at
room temperature. CD3 and CD8 antigen retrieval
was performed for 20 min using Bond Epitope
Retrieval Solution 2 (Leica Biosystems). Example of
CD8 and CD3 staining are shown in Figure 1.
Immunoscore determination
CD31 and CD81 cells were assessed by digital
image analysis. Stained TMA block sections from
representative areas of the tumour centre and inva-
sive front were scanned using an Aperio digital slide
scanner (Leica Biosystems), followed by analysis
using an ImageJ-based program to count the numbers
of CD31 and CD81 cells. Cells were identified
based on their size, shape, and staining intensity as
described earlier by V€ayrynen et al [22]. In order to
minimize selection bias as well as the number of dis-
carded patients from the study because of unrepresen-
tative or inadequate samples (tissue cores), we took
two cores from the tumour centre and two cores from
the invasive front. From each core, we had one sec-
tion cut for both lymphocyte stains. If the sample
taken from the original tumour tissue block did not
represent tissue area that was targeted (eg, core taken
from invasion front) it was considered unrepresenta-
tive. Inadequate means that majority of the tissue
Figure 1. Examples of (A) CD8 staining from tumour centre, (B) CD3 staining from tumour centre, (C) CD8 staining from tumour
invasive front, and (D) CD3 staining from tumour invasive front.
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core was for example torn off from the TMA section.
Each tissue core was 600 lm in diameter and from
each patient we had a minimum of four representa-
tive core sections (one core section from tumour
centre and one from invasive front for both stains).
Eighty-nine and eighty-eight tumour centre core sec-
tions were abandoned for CD8 and CD3, and 38 and
42 invasive front core sections were abandoned for
CD8 and CD3, respectively, as they were either
unrepresentative or inadequate. The average area ana-
lyzed from each patient was 0.52 mm2 for CD8 and
CD3 at the tumour centre and 0.54 mm2 for CD8 and
CD3 at the invasive front, giving a total analyzed
area of 2.12 mm2 for each patient. All of the auto-
matically analyzed sections were individually
reviewed and values were corrected manually in
cases with inaccurate results. Of the four acquired
section pairs (two core sections from the tumour
centre and two from the invasive front for both
stains), we selected the sections with the highest lym-
phocyte count in order to minimize the number of
false negative results. IHC stains were always
assessed without knowledge of the clinical data.
The immunoscore was generated from four sam-
ples: one core section from the tumour centre and
one core section from the invasive front for both
lymphocyte stains (CD3 and CD8). The sections
were determined to have either high or low lympho-
cyte count (number of cells/mm2). The cut-off values
were obtained from receiver operating characteristic
(ROC)-curves drawn for each group in relation to
disease-specific 3-year mortality. ROC-curves give a
likelihood ratio for disease-specific mortality for each
lymphocyte count, so we can select the value with
optimal sensitivity and specificity to separate patients
into those who are more likely to have the end point
and those who would not. Table 1 shows the cut-off
values with likelihood ratios and area under the curve
(AUC) for the CD8 and CD3 tumour centre and CD8
and CD3 invasive front ROC-curves. One Immuno-
score point is given for each section with a high lym-
phocyte count so that in IS 4 all the sections had a
high lymphocyte count and in IS 0 none of the sec-
tions had a high count.
Statistical analyses
Categorical data were compared using Pearson’s chi-
square or Mantel-Haenszel tests. The Kaplan-Meier
method was used to calculate disease-free survival
(DFS), disease-specific survival (DSS), and overall
survival (OS), and the log-rank test was used to com-
pare differences. Survival times for DSS and OS were
calculated from the date of surgery to the time of
death or the end of follow-up. For DFS, the endpoint
was the date of cancer recurrence after radical surgery
or the end of follow-up. Death within 30 days follow-
ing surgery was considered postoperative, and metasta-
sis within 6 months after surgery was considered
synchronous. Univariable and multivariable Cox pro-
portional hazards regression models were used to ana-
lyze prognostic factors for DFS, DSS, and OS. Only
variables with a P value of< 0.20 in univariable anal-
ysis were included in the multivariable analysis with
age and gender. Among AJCC/UICC stage I patients
there were no cancer deaths; thus, these patients were
excluded from multivariable analysis for DSS. P val-
ues of< 0.05 were considered significant. Statistical
analyses were conducted using SPSS Statistics for
Windows (release 23.0.0.0; SPSS, Inc.).
Table 1. Immunoscore cut-off values
Cut-off value
(cells/mm2)
AUC
(95% CI)
Sensitivity
(95% CI)
Specificity
(95% CI)
Likelihood
Ratio
CD8 Tumour centre:
3-year DSS 226 0.64 (0.57 to 0.70) 0.74 (0.64 to 0.82) 0.53 (0.48 to 0.58) 1.57 (1.34 to 1.83)
5-year DSS 226 0.64 (0.58 to 0.69) 0.72 (0.64 to 0.80) 0.54 (0.49 to 0.59) 1.57 (1.34 to 1.83)
CD3 Tumour centre
3-year DSS 339 0.64 (0.59 to 0.70) 0.50 (0.40 to 0.60) 0.74 (0.69 to 0.78) 1.93 (1.50 to 2.48)
5-year DSS 339 0.64 (0.58 to 0.70) 0.50 (0.41 to 0.59) 0.75 (0.70 to 0.79) 1.98 (1.54 to 2.54)
CD8 Tumour invasive margin:
3-year DSS 286 0.65 (0.59 to 0.71) 0.59 (0.49 to 0.69) 0.68 (0.63 to 0.73) 1.85 (1.49 to 2.29)
5-year DSS 290 0.65 (0.58 to 0.70) 0.58 (0.49 to 0.67) 0.68 (0.63 to 0.73) 1.83 (1.48 to 2.26)
CD3 Tumour invasive margin:
3-year DSS 618 0.65 (0.59 to 0.70) 0.65 (0.55 to 0.74) 0.63 (0.58 to 0.67) 1.74 (1.44 to 2.10)
5-year DSS 618 0.65 (0.59 to 0.71) 0.63 (0.54 to 0.72) 0.63 (0.58 to 0.68) 1.73 (1.43 to 2.09)
Cut-off values for the tumour centre and invasive margin were selected from 3-year disease-specific survival (DSS) ROC curves to identify the most aggressive
tumours. Only a few cancer deaths occurred between 3 and 5 years, and the cut-off values from the 5-year ROC curve did not significantly differ from the
3-year cut-off values. AUC, area under the curve; CI, confidence interval.
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Ethical aspects
The study was approved by the ethical committee of
the Central Finland Central Hospital. Authorization
for use of the patient registry was obtained from the
National Supervisory Authority for Welfare and
Health (Valvira).
Results
Clinicopathological characteristics
Table 2 shows the patients’ clinicopathological
details including AJCC/UICC stage and MMR/BRAF
mutation status distribution. Within the study
Table 2. Clinicopathological variables and their associations with Immunoscore
Immunoscore 0 & 1
(N5 142)
N (% of row)
Immunoscore 2 & 3
(N5 208)
N (% of row)
Immunoscore 4
(n5 160)
N (% of row)
Total
(n5 510)
N (% of column) p
Age:
<65 years 44 (31) 55 (39) 43 (30) 142 (28) 0.913*
65 to 75 years 32 (22) 67 (46) 48 (33) 147 (29)
>75 years 66 (30) 86 (40) 69 (31) 221 (43)
Gender:
Male 66 (29) 95 (42) 65 (29) 226 (44) 0.520
Female 76 (27) 113 (40) 95 (34) 284 (56)
Tumour location:
Right hemicolon 73 (25) 113 (39) 101 (35) 287 (56) 0.094
Left hemicolon 69 (31) 95 (43) 59 (27) 223 (44)
T stage
1 5 (21) 10 (42) 9 (38) 24 (5) 0.001*
2 15 (20) 32 (43) 28 (37) 75 (15)
3 77 (24) 136 (43) 104 (33) 317 (62)
4 45 (48) 30 (32) 19 (20) 94 (18)
Lymph node metastasis:
No 59 (20) 121 (41) 113 (39) 293 (58) <0.001
Yes 83 (38) 87 (40) 47 (22) 217 (42)
Distant Metastasis:
No 112 (25) 184 (41) 150 (34) 446 (88) <0.001
Yes 30 (47) 24 (38) 10 (16) 64 (12)
AJCC/UICC Stage:
I 16 (21) 32 (41) 30 (39) 78 (15) <0.001*
II 40 (20) 83 (41) 79 (39) 202 (40)
III 55 (34) 68 (42) 38 (24) 161 (32)
IV 31 (45) 25 (36) 13 (19) 69 (14)
Lymph node ratio:
<0.12 11 (20) 28 (52) 15 (28) 54 (11) 0.127*
0.12 to 0.30 23 (42) 20 (36) 12 (22) 55 (11)
>0.30 21 (40) 20 (39) 11 (21) 52 (10)
Perineural invasion:
No 116 (25) 193 (42) 151 (33) 460 (90) <0.001
Yes 26 (52) 15 (30) 9 (18) 50 (10)
Lymphovascular invasion:
No 110 (26) 178 (41) 144 (33) 432 (85) 0.009
Yes 32 (41) 30 (38) 16 (21) 78 (15)
MMR status:
MSS 129 (31) 181 (43) 109 (26) 419 (82) <0.001
MSI 13 (14) 27 (30) 51 (56) 91 (18)
BRAF status:
BRAF wild-type 122 (30) 180 (44) 108 (27) 410 (80) <0.001
BRAF mutation 17 (22) 21 (27) 41 (53) 79 (15)
MMR/BRAF combinations
MSS/BRAFwt 118 (31) 168 (44) 96 (25) 382 (75) <0.001
MSS/BRAFmut 9 (38) 8 (33) 7 (29) 24 (5)
MSI/BRAFwt 4 (14) 12 (43) 12 (43) 28 (5)
MSI/BRAFmut 8 (15) 13 (24) 34 (62) 55 (11)
*Mantel-Haenszel test used.
MMR, mismatch repair; MSS, micro-satellite stable; MSI, micro-satellite instable; AJCC, The American Joint Committee on Cancer; UICC, Union for International
Cancer Control; BRAFwt, BRAF wild-type; BRAFmut, BRAF mutation.
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population, the median follow-up time was 6.0
years (IQR, 1.7 to 9.0 years) and the median age at
the time of surgery was 73 years (IQR, 64 to 79
years). R0 resection of the primary tumour was
achieved in 435 of the 510 patients (85%). Non-
radical operation was performed in 75 patients
(15%), including 63 with stage IV disease with car-
cinosis or unresectable distant metastasis, nine with
stage II or III disease showing local invasion to
adjacent tissues, and one patient with abdominal
wound recurrence. The median number of exam-
ined lymph nodes was 11 (IQR, 6 to 17). Postoper-
ative death was recorded for 27 patients (5%). Of
the 483 patients alive after surgery, 162 (34%)
received adjuvant chemotherapy.
Immunoscore and association with other
clinicopathological parameters
IS distribution in our series was as follows: IS0, 16%;
IS1, 12%; IS2, 20%; IS3, 21%; and IS4, 31%. Lower IS
was associated with increasing AJCC/UICC stage, as
well as with increasing T stage, presence of lymph node
and distant metastasis, and perineural or lymphovascular
invasion (Table 2, Figure 2A). IS was not significantly
associated with LNR, age, sex, or tumour location. IS dis-
tribution is shown in relation to MMR status and in rela-
tion to MMR/BRAF mutation sub-classification in Table
2 and Figure 2B, respectively. Most MSI tumours had
high IS, with 56% belonging to the IS4 group. BRAF
mutation occurred predominantly in MSI tumours with
IS4 (Table 2).
Figure 2. Distributions of (A) AJCC/UICC stage and (B) MMR/BRAF mutation status between different Immunoscore (IS) classes; and
(C) disease-free survival and (D) disease-specific survival for different IS classes.
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Survival
Higher IS was related to improved 5-year DFS, DSS,
and OS (Table 3, Figure 2C,D) within the entire study
population and in both the MSS and MSI subgroups.
Among MSS cases (n5 419), 5-year DFS was 61%
for IS0 and IS1, 79% for IS2, and IS3 and 92% for
IS4 (p< 0.001). For these respective IS groups, 5-year
DSS was 49, 76, and 89% (p< 0.001), and 5-year OS
was 42, 64, and 77% (p5 0.001). Among MSI cases
(n5 91), 5-year DFS was 75% for IS0 and IS1, 90%
Table 3. Survival according to clinicopathological variables and Immunoscore
Disease-free survival
(N5 417)
Disease-specific survival
(N5 510)
Overall survival
(N5 510)
Total N 5-year survival p Total N 5-year survival p Total N 5-year survival p
Age:
<65 years 117 77% 0.103 142 74% 0.102 142 71% <0.001
65 to 75 years 125 87% 147 80% 147 71%
>75 years 175 78% 221 68% 221 48%
Gender:
Male 183 82% 0.925 226 71% 0.415 226 56% 0.047
Female 234 80% 284 76% 284 66%
AJCC/UICC stage:
I 75 99% <0.001 78 100% <0.001 78 77% <0.001
II 190 84% 202 89% 202 73%
III 146 69% 161 71% 161 62%
IV 6 33% 69 9% 69 7%
Lymph node ratio:
<0.12 54 83% <0.001 54 89% <0.001 54 80% <0.001
0.12 to 0.30 49 75% 55 77% 55 69%
>0.30 43 43% 52 45% 52 37%
Perineural invasion:
No 390 83% <0.001 460 78% <0.001 460 64% <0.001
Yes 27 44% 50 39% 50 36%
Lymphovascular invasion:
No 374 84% <0.001 432 81% <0.001 432 68% <0.001
Yes 43 52% 78 32% 78 24%
Immunoscore:
0 54 58% <0.001 81 47% <0.001 81 40% <0.001
1 45 68% 61 55% 61 44%
2 86 78% 102 75% 102 66%
3 92 82% 106 80% 106 61%
4 140 94% 160 89% 160 76%
IS within adjuvant chemotherapy group:
0 to 1 45 51% 0.003 47 55% <0.001 47 55% 0.009
2 to 3 72 72% 73 82% 73 77%
4 40 84% 42 85% 42 76%
MMR status:
MSS 337 78% 0.003 419 71% 0.003 419 60% 0.558
MSI 80 93% 91 86% 91 66%
BRAF status:
BRAF wild-type 339 78% 0.029 410 74% 0.941 410 62% 0.037
BRAF mutation 61 91% 79 72% 79 54%
MMR/BRAF mutation status:
MSS/BRAFwt 315 77% 0.043 382 73% <0.001 382 62% <0.001
MSS/BRAFmut 11 82% 24 42% 24 29%
MSI/BRAFwt 24 90% 28 88% 28 68%
MSI/BRAFmut 50 93% 55 85% 55 66%
Immunoscore (IS) includes all the patients from the study.
The IS within the adjuvant chemotherapy group includes patients who received adjuvant chemotherapy (medically fit patients having stage III tumours or high-
risk stage II disease). Stage IV patients are excluded because they had chemotherapy that differs from standard adjuvant treatment.
The Kaplan-Meier method was used to calculate disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS), and the log-rank test was
used to compare differences.
CI, confidence interval; HR, hazard ratio; MMR, mismatch repair; MSI, microsatellite instability; MSS, microsatellite stable; AJCC, The American Joint Committee
on Cancer; UICC, Union for International Cancer Control; BRAFwt, BRAF wild-type; BRAFmut, BRAF mutation.
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for IS2 and IS3, and 98% for IS4 (p5 0.047). For
these respective IS groups, 5-year DSS was 71, 88,
and 89% (p5 0.029) and 5-year OS was 39, 63, and
75% (p5 0.008). MMR status was a prognostic factor
according to Kaplan-Meier survival analyses, with
MSI patients showing better DFS and DSS (Table 3).
Figure 3. Disease-free survival according to Immunoscore (IS) in AJCC/UICC stage II (A) and stage III (B) disease. Disease-specific sur-
vival according to IS in AJCC/UICC stage II (C) and stage III (D) disease. (E) Disease-specific survival according to IS in AJCC/UICC
stage IV disease.
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Table 3 shows DFS, DSS, and OS according to
AJCC/UICC stage. In AJCC/UICC stages II and III,
higher IS was associated with improved DFS (Figure
3A,B) and DSS (Figure 3C,D). IS was also prognostic
within the patient group with AJCC/UICC stage IIa
disease (T3, N0; n5 171), with 5-year DFS rates of
73% for IS0 and IS1, 88% for IS2 and IS3, and 95%
for IS4 (p5 0.002), and respective 5-year DSS rates of
82, 94, and 97% (p5 0.018). Moreover, IS was prog-
nostic for DFS, DSS, and OS among those patients
with stage II or III disease who received adjuvant
chemotherapy after surgery (n5 162). In AJCC/UICC
stage IV disease (n5 69), higher IS was related to
improved DSS (Figure 3E). The effect of IS by
Table 4. Multivariable analysis with Cox proportional hazard model
Univariable
analysis
Disease-free survival (DFS)
(n5 396)
Disease-specific survival (DSS)
(n5 432)
Overall survival (OS)
(n5 489)
p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age:
<65 years DFS: 0.109* 1 0.195* 1 0.023* 1 <0.001*
65 to 75 years DSS: 0.105* 0.73 (0.39–1.39) 1.14 (0.70–1.87) 1.41 (0.96–2.06)
>75 years OS: <0.001* 1.27 (0.76–2.12) 1.72 (1.14–2.59) 3.14 (2.26–4.35)
Gender: DFS: 0.925
Male DSS: 0.416 0.93 (0.59–1.49) 0.769 0.98 (0.69–1.39) 0.891 1.29 (1.00–1.65) 0.049
Female OS: 0.048 1 1 1
AJCC/UICC stage:
I DFS: <0.001* 1 0.004* Excluded <0.001* 1 <0.001*
II DSS: <0.001* 11.72 (1.60–86.08) 1 0.86 (0.58–1.29)
III OS: <0.001* 18.27 (2.48–134.37) 1.99 (1.22–3.25) 0.99 (0.65–1.53)
IV 39.18 (4.18–367.28) 14.80 (8.88–24.67) 5.51 (3.45–8.80)
Perineural invasion:
No DFS: <0.001 1 0.092 1 0.588 1 0.737
Yes DSS: <0.001 1.74 (0.91–3.30) 1.12 (0.74–1.72) 1.07 (0.73–1.56)
OS: <0.001
Lymphovascular invasion:
No DFS: <0.001 1 0.023 1 <0.001 1 <0.001
Yes DSS: <0.001 1.90 (1.09–3.29) 2.72 (1.86–3.97) 2.30 (1.68–3.14)
OS: <0.001
Immunoscore:
0 DFS: <0.001* 5.68 (2.43–13,31) 0.001* 4.48 (2.49–8.05) <0.001* 2.47 (1.66–3.67) <0.001*
1 DSS: <0.001* 4.05 (1.64–9.97) 3.00 (1.58–5.70) 2.00 (1.29–3.08)
2 OS: <0.001* 3.28 (1.41–7.64) 2.18 (1.19–4.02) 1.44 (0.98–2.12)
3 2.51 (1.05–6.00) 1.44 (0.75–2.75) 1.41 (0.95–2.07)
4 1 1 1
MMR-status: DFS: 0.005 Excluded
MSS DSS: 0.003 1 0.126 1 0.271
MSI OS: 0.558 0.42 (0.14–1.27) 0.70 (0.37–1.33)
BRAF-status: DFS: 0.036 Excluded
BRAF wild-type DSS: 0.941 1 0.760 1 0.031
BRAF mutation OS: 0.038 0.84 (0.28–2.53) 1.46 (1.04–2.07)
Tumour location: DFS: 0.733 Excluded from all analyses
Right hemicolon DSS: 0.332
Left hemicolon OS: 0.345
Univariate analyses were performed with the following reference categories: 65 years, male gender, Stage 1, no perineural invasion, no lymphovascular invasion,
Immunoscore 4, MSS-status, BRAF wild type and tumour location in the left hemicolon. Only variables with a P value of <0.20 in univariable analysis were
included in the multivariable analysis with age and gender. There were 396 cases available for analysis of DFS, 432 for DSS, and 489 for OS. Patients with pTNM
stage I disease (n5 78) were discarded from DSS analysis because there was no disease-specific mortality. Ninety-three cases were excluded from DFS analysis
due to either existing metastasis or non-radical surgery, 4 patients died before earliest event (recurrence) in a stratum, and an additional 17 cases had undeter-
mined BRAF status. Due to missing data (BRAF status) 21 cases were excluded from OS analysis.
*p for linearity.
CI, confidence interval; HR, hazard ratio; MMR, mismatch repair; MSI, microsatellite instability; MSS, microsatellite stable; AJCC, The American Joint Committee
on Cancer; UICC, Union for International Cancer Control.
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AJCC/UICC stage on DFS and DSS was not investi-
gated in stage I disease due to the low number of events
(one recurrence, no cancer deaths). Increasing lymph
node ratio was associated with lower DFS, DSS, and
OS rates, but was not significantly associated with IS.
Prognostic factors for survival
Multivariable regression analyses revealed that IS,
AJCC/UICC stage, and lymphovascular invasion were
independent prognostic factors for DFS, DSS, and OS
(Table 4). Additionally, age was independent prognos-
tic factor for DSS and OS. Gender and BRAF mutation
were independent prognostic factors for OS (Table 4).
In stage III disease, and with adjustment for age,
gender, perineural, and lymphovascular invasion, IS,
MMR status (in DFS and DSS), BRAF mutation sta-
tus (in DFS and OS), we found that increasing LNR
was an independent prognostic factor for worse DFS,
DSS, and OS. With LNR< 0.12 used as the refer-
ence, the hazard ratio (HR) for DFS was 6.05 for
LNR> 0.30 (95% CI, 2.52 to 14.49; p< 0.001), the
HR for DSS was 4.06 for LNR> 0.30 (95% CI, 1.82
to 9.09; p5 0.001), and the HR for OS was 3.33 for
LNR> 0.30 was (95% CI, 1.77 to 6.27; p< 0.001).
Discussion
Our present results reveal that Immunoscore is an independ-
ent prognostic factor for DFS, DSS, and OS regardless of
tumour MMR status. This finding is in accordance with
previous data [9]. The prognostic significance of IS for both
DFS and DSS was evident in stages II and III. Importantly,
among stage IIa patients who do not usually receive adju-
vant chemotherapy, IS could identify patients with higher
risk of recurrence and cancer-related death. Even among
stage IV patients, higher IS was associated with improved
DSS. We also found that high IS was significantly associ-
ated with a less invasive tumour phenotype (including
reduced perineural and lymphovascular invasion rates) and
with decreased risk of lymph node and distant metastases.
This suggests that an improved cytotoxic immune response
against tumour cells may also constrain metastatic progres-
sion. Among patients who received adjuvant chemotherapy,
low IS corresponded with poor prognosis and high IS with
good prognosis despite additional treatments.
There are two different aetiopathological pathways in
CRC development: the MSI pathway that induces hyper-
mutated cancers, and the chromosome instable pathway
that generates MSS non-hypermutated cancers. In our
study, IS was a prognostic factor for MSS colon cancer
lacking the highly immunogenic response caused by
MSI. IS was also prognostic for better survival in MSI
disease. These findings are similar to previously reported
data [9]. Although CRCs with microsatellite instability
generate more DNA mutations than stable CRCs [11],
they have a better prognosis [11–14,23,24]. Our current
results indicate that MSI induces enhanced cytotoxic
immunogenic reactions. This improved immune
response is likely explained by the high abnormal protein
burden caused by hundreds of unpredictable mutations,
and this strengthened host immune response may explain
the survival benefits seen with MSI CRCs.
When categorizing IS, the selection of repeatable cut-off
values is an important practical issue. In their preliminary
study, Galon et al selected cut-off values with the smallest
P value method, and found that the proportion of IS 0 cases
was only 4% [7]. In our study, we determined cut-off val-
ues with optimal sensitivity and specificity based on ROC
curves related to disease-specific 3-year mortality. This
resulted in a more balanced distribution of patients among
the five IS groups, and still demonstrated substantial pre-
dictive significance of IS. Several other factors may impact
the distribution of IS categories and, therefore, cut-off val-
ues are case dependent to some extent. For example, the
section thickness, representativeness of punch areas and
immunohistochemical staining platforms may vary
between different studies, potentially hindering the creation
of universal standardized cut-off values.
To date, AJCC/UICC staging is the best CRC
prognostic indicator. However, while it reflects
tumour burden at the time of diagnosis, it does not
provide information about the biological features of
the cancer. In our study, IS was not superior to
AJCC/UICC staging as an independent prognostic
factor, but the lowest and highest IS groups could
clearly differentiate the patients with the worst and
best prognosis in each AJCC/UICC-stage. Thus, a
combination of AJCC/UICC staging and IS might
provide more exact prognostic information, allowing
clinicians to better tailor treatment [10]. It has also
been proposed that lymph node ratio may be an addi-
tional prognostic tool for stage III CRC patients [21].
Our results support the earlier findings on this sub-
ject; lymph node ratio was not associated with IS and
could offer additional prognostic information.
As suggested in earlier studies, BRAF mutation is
not associated with worse prognosis in MSI tumours
[12,25,26], but is an independent risk factor for
decreased survival in MSS disease [12,16–18]. In our
study, most BRAF mutations (70%) were found in
MSI tumours. High IS was associated with BRAF
mutations in MSI tumours, but it is possible that
immunogenicity develops due to the hypermutability
of MSI tumours. It remains unclear whether BRAF
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itself is immunogenic, since IS distribution was not
influenced by BRAF mutation in MSS tumours.
In conclusion, our data demonstrate the use of IS
in the classification of colon cancer prognosis across
AJCC/UICC stages. Particularly among stage IIa
colon cancer patients, IS may prove to be an impor-
tant prognostic marker for identifying patients who
are likely to benefit from adjuvant treatments. A
strength of our study is that patients with colon can-
cers were classified and treated used a contemporary
multidisciplinary approach. Moreover, the follow-up
time was long and complete for each patient. Future
randomized studies are needed to examine the com-
bined use of AJCC/UICC stage and IS to select colon
cancer patients for individualized adjuvant therapy.
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